Blue Water Vaccines Inc to Present at World Vaccine Congress Washington 2022
April 11 2022 - 8:56AM
Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the
Company”) a biopharmaceutical company developing transformational
vaccines to address significant global health challenges, today
announced that Brian Price, Ph.D., Head of Technology Strategy,
will deliver a presentation during the World Vaccine Congress 2022
in Washington, DC. BWV will present on its universal influenza
vaccine candidate, which utilizes the exclusively licensed epitopes
of limited variability identified by scientists at The University
of Oxford.
Session details are as follows:
Date: |
Wednesday, April 20, 2022 |
Time: |
5:55
p.m. Eastern Daylight Time (EDT) |
Title: |
BWV-101
- Universal Influenza Vaccine Program |
BWV Participant: |
Brian
Price, Ph.D., Head of Technology Strategy |
“We are honored to present at such a prestigious conference
focused on the development of novel vaccines,” said Joseph
Hernandez, Chief Executive Officer of Blue Water Vaccines. “In
collaboration with The University of Oxford, we are committed to
exploring the development of a universal influenza vaccine via
epitopes of limited variability and are excited to present our
technology to peers from around the world.”
BWV management will be available during the events for
one-on-one meetings. Interested parties may request a one-on-one
meeting at ehenderson@bluewatervaccines.com or contact
BWV at (513) 620-4101.
About Blue Water Vaccines
Blue Water Vaccines Inc. is a biopharmaceutical company focused
on developing transformational vaccines to address significant
health challenges globally. Headquartered in Cincinnati, OH, the
company holds the rights to proprietary technology developed at the
University of Oxford, Cincinnati Children's Hospital Medical Center
(CCHMC), and St. Jude Children's Hospital. The company is
developing a universal flu vaccine that will provide protection
from all virulent strains in addition to licensing a novel
norovirus (NoV) S&P nanoparticle versatile virus-like particle
(VLP) vaccine platform from CCHMC to develop vaccines for multiple
infectious diseases, including norovirus/rotavirus and malaria,
among others. Additionally, Blue Water Vaccines is developing a
Streptococcus pneumoniae (pneumococcus) vaccine candidate, designed
to specifically prevent the highly infectious middle ear
infections, known as Acute Otitis Media (AOM), in children. For
more information, visit www.bluewatervaccines.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking
within the meaning of the Private Securities Litigation Reform Act
of 1995. These statements may be identified by the use of
forward-looking words such as “anticipate,” “believe,” “forecast,”
“estimate,” “expect,” and “intend,” among others. These
forward-looking statements are based on BWV’s current expectations
and actual results could differ materially. There are a number of
factors that could cause actual events to differ materially from
those indicated by such forward-looking statements. These factors
include, but are not limited to, risks related to the development
of BWV’s vaccine candidates, including, but not limited to BWV-301;
the failure to obtain FDA clearances or approvals and noncompliance
with FDA regulations; delays and uncertainties caused by the global
COVID-19 pandemic; risks related to the timing and progress of
clinical development of our product candidates; our need for
additional financing; uncertainties of patent protection and
litigation; uncertainties of government or third party payor
reimbursement; limited research and development efforts and
dependence upon third parties; and substantial competition. As with
any vaccine under development, there are significant risks in the
development, regulatory approval and commercialization of new
products. BWV does not undertake an obligation to update or revise
any forward-looking statement. Investors should read the risk
factors set forth in BWV’s registration statement on Form S-1
relating to its initial public offering, initially filed with the
Securities and Exchange Commission (the “SEC”) on October 10, 2021,
as amended, and periodic reports filed with the SEC on or after the
date thereof. All of BWV’s forward-looking statements are expressly
qualified by all such risk factors and other cautionary statements.
The information set forth herein speaks only as of the date
thereof.
Contact Information:Media Relations513-620-4101Email:
media@bluewatervaccines.com
Blue Water Biotech (NASDAQ:BWV)
Historical Stock Chart
From Jul 2024 to Aug 2024
Blue Water Biotech (NASDAQ:BWV)
Historical Stock Chart
From Aug 2023 to Aug 2024